|
1
|
Siegel RL, Miller KD, Goding Sauer A,
Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal
A: Colorectal cancer statistics, 2020. CA Cancer J Clin.
70:145–164. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Song M, Garrett WS and Chan AT: Nutrients,
foods, and colorectal cancer prevention. Gastroenterology.
148:1244–1260.e16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhu H: Targeting forkhead box
transcription factors FOXM1 and FOXO in leukemia (review). Oncol
Rep. 32:1327–1334. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Golson ML and Kaestner KH: Fox
transcription factors: from development to disease. Development.
143:4558–4570. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Laissue P: The forkhead-box family of
transcription factors: key molecular players in colorectal cancer
pathogenesis. Mol Cancer. 18:52019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nakano I: Transcription factors as master
regulator for cancer stemness: Remove milk from fox? Expert Rev
Anticancer Ther. 14:873–875. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zong Y, Miao Y, Li W, Zheng M, Xu Z, Gao
H, Feng W, Xu Z, Zhao J, Shen L and Lu A: Combination of FOXD1 and
Plk2: A novel biomarker for predicting unfavourable prognosis of
colorectal cancer. J Cell Mol Med. 26:3471–3482. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao YF, Zhu T, Mao XY, Mao CX, Li L, Yin
JY, Zhou HH and Liu ZQ: Silencing of forkhead box D1 inhibits
proliferation and migration in glioma cells. Oncol Rep.
37:1196–1202. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nakayama S, Soejima K, Yasuda H, Yoda S,
Satomi R, Ikemura S, Terai H, Sato T, Yamaguchi N, Hamamoto J, et
al: FOXD1 expression is associated with poor prognosis in non-small
cell lung cancer. Anticancer Res. 35:261–268. 2015.PubMed/NCBI
|
|
10
|
Li D, Fan S, Yu F, Zhu X, Song Y, Ye M,
Fan L and Lv Z: FOXD1 promotes cell growth and metastasis by
activation of vimentin in NSCLC. Cell Physiol Biochem.
51:2716–2731. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pan F, Li M and Chen W: FOXD1 predicts
prognosis of colorectal cancer patients and promotes colorectal
cancer progression via the ERK 1/2 pathway. Am J Transl Res.
10:1522–1530. 2018.PubMed/NCBI
|
|
12
|
Lytle NK, Barber AG and Reya T: Stem cell
fate in cancer growth, progression and therapy resistance. Nat Rev
Cancer. 18:669–680. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Visvader JE and Lindeman GJ: Cancer stem
cells: current status and evolving complexities. Cell Stem Cell.
10:717–728. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takebe N, Miele L, Harris PJ, Jeong W,
Bando H, Kahn M, Yang SX and Ivy SP: Targeting notch, hedgehog, and
Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin
Oncol. 12:445–464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li F, Tiede B, Massagué J and Kang Y:
Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res.
17:3–14. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu CC, Chen C, Xu ZQ, Zhao JK, Ou BC, Sun
J, Zheng MH, Zong YP and Lu AG: CCR6 promotes tumor angiogenesis
via the AKT/NF-κB/VEGF pathway in colorectal cancer. Biochim
Biophys Acta Mol Basis Dis. 1864:387–397. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tirino V, Desiderio V, Paino F, De Rosa A,
Papaccio F, La Noce M, Laino L, De Francesco F and Papaccio G:
Cancer stem cells in solid tumors: An overview and new approaches
for their isolation and characterization. FASEB J. 27:13–24. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao J, Ou B, Feng H, Wang P, Yin S, Zhu
C, Wang S, Chen C, Zheng M, Zong Y, et al: Overexpression of CXCR2
predicts poor prognosis in patients with colorectal cancer.
Oncotarget. 8:28442–28454. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu YY and Yuan Z: Pancreatic cancer stem
cells. Am J Cancer Res. 26:894–906. 2015.PubMed/NCBI
|
|
20
|
André T, Boni C, Mounedji-Boudiaf L,
Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan
P, Bridgewater J, et al: Oxaliplatin, fluorouracil, and leucovorin
as adjuvant treatment for colon cancer. N Engl J Med.
350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dongre A and Weinberg RA: New insights
into the mechanisms of epithelial-mesenchymal transition and
implications for cancer. Nat Rev Mol Cell Biol. 20:69–84. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alberts SR, Horvath WL, Sternfeld WC,
Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S,
Sargent DJ and Donohue JH: Oxaliplatin, fluorouracil, and
leucovorin for patients with unresectable liver-only metastases
from colorectal cancer: A north central cancer treatment group
phase II study. J Clin Oncol. 23:9243–9249. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Argilés G, Tabernero J, Labianca R,
Hochhauser D, Salazar R, Iveson T, Laurent-Puig P, Quirke P,
Yoshino T, Taieb J, et al: Localised colon cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 31:1291–1305. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Findlay VJ, Wang C, Watson DK and Camp ER:
Epithelial-to-mesenchymal transition and the cancer stem cell
phenotype: Insights from cancer biology with therapeutic
implications for colorectal cancer. Cancer Gene Ther. 21:181–187.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen Y, Liang W, Liu K and Shang Z: FOXD1
promotes EMT and cell stemness of oral squamous cell carcinoma by
transcriptional activation of SNAI2. Cell Biosci. 11:1542021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li CH, Chang YC, Hsiao M and Liang SM:
FOXD1 and Gal-3 form a positive regulatory loop to regulate lung
cancer aggressiveness. Cancers (Basel). 11:18972019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao YF, Zhao JY, Yue H, Hu KS, Shen H,
Guo ZG and Su XJ: FOXD1 promotes breast cancer proliferation and
chemotherapeutic drug resistance by targeting p27. Biochem Biophys
Res Commun. 456:232–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ombrato L, Nolan E, Kurelac I, Mavousian
A, Bridgeman VL, Heinze I, Chakravarty P, Horswell S,
Gonzalez-Gualda E, Matacchione G, et al: Metastatic-niche labelling
reveals parenchymal cells with stem features. Nature. 572:603–608.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Carstens MR, Fisher RC, Acharya AP,
Butterworth EA, Scott E, Huang EH and Keselowsky BG: Drug-eluting
microarrays to identify effective chemotherapeutic combinations
targeting patient-derived cancer stem cells. Proc Natl Acad Sci
USA. 112:8732–8737. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wilson MM, Weinberg RA, Lees JA and Guen
VJ: Emerging mechanisms by which EMT programs control stemness.
Trends Cancer. 6:775–780. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hirabayashi Y, Itoh Y, Tabata H, Nakajima
K, Akiyama T, Masuyama N and Gotoh Y: The Wnt/β-catenin pathway
directs neuronal differentiation of cortical neural precursor
cells. Development. 131:2791–2801. 2004. View Article : Google Scholar : PubMed/NCBI
|
